{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Issues in Combination Cancer Therapies with Immune Checkpoint Inhibitors

Purpose of Activity

To provide information on issues related to combination cancer therapies with immune checkpoint inhibitors.

Learning Objectives/Outcomes

After completing this continuing education activity you will be able to:

  1. Critique developing new immunotherapy combinations and the requirements for the next treatment frontier.
  2. Assess challenges raised by immune checkpoint inhibitors used in combination regimens.
Price: $12.95

Credits:

  • ANCC 1.0 CH
  • DC - BON 1.0 CH
  • FL - BON 1.0 CH
  • GA - BON 1.0 CH

Lippincott Professional Development is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, and Georgia Board of Nursing, #50-1223.







Test Code: OT0918
Published: Sep 2018
Expires: 9/4/2020
Sources: Oncology Times
Passing Score: 7/10 (70%)
Authors: Peggy Eastman
Categories: Oncology
Specialties: Oncology
Topics: Cancer , Immunotherapy